In Phase 3 TRIUMPH-1 data, dysesthesia occurred in 5.1%, 12.3%, and 12.5% of participants taking retatrutide 4 mg, 9 mg, and 12 mg, compared with 0.9% of participants receiving placebo
PubMed Discontinuing glucagon-like peptide-1 receptor agonists and body habitus Used for pages discussing stopping therapy, weight regain, and long-term planning
Phentermine hits faster and can show results within days, but its only meant for short-term use (around 12 weeks) and is a controlled substance with abuse potential
Liquids go down easier, and this combo still gives me protein and fiber
Glossary CKD c hronic kidney disease CNS central nervous system CVD c ardiovascular disease FDA Food and Drug Administration GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HF Heart failure MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PAD peripheral arterial disease SC subcutaneous T2DM type 2 diabetes mellitus U.S
Lancet Diabetes Endocrinol (2018) 6:27586
